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ABSTRACT
Purpose Here we show how amodel-based approach may be
used to provide further insight into the role of clinical and
demographic covariates on the progression of iron overload.
The therapeutic effect of deferoxamine is used to illustrate the
application of disease modelling as a means to characterising
treatment response in individual patients.
Methods Serum ferritin, demographic characteristics and in-
dividual treatment data from clinical routine practice on 27
patients affected by β-thalassaemia major were used for the
purposes of this analysis. The time course of serum ferritin was
described by a hierarchical nonlinear mixed effects model, in
which compliance was parameterised as a covariate factor.
Modelling and simulation procedures were implemented in
NONMEM (7.2.0).
Results A turnover model best described serum ferritin
changes over time, with the effect of blood transfusions
introduced on the ferritin conversion rate and the effect of
deferoxamine on the elimination parameter (Kout) in a pro-
portional manner. The results of the simulations showed
that poor quality of execution is preferable over drug
holidays; and that independently of the compliance pat-
tern, the therapeutic intervention is not effective if
>60% of the doses are missed.
Conclusions Modelling of ferritin response enables character-
isation of the dynamics of iron overload due to chronic trans-
fusion. The approach can be used to support decision making
in clinical practice, including personalisation of the dose for
existing and novel chelating agents.
KEY WORDS adherence . deferoxamine . disease
modelling . dose rationale . iron overload . PKPDmodelling
ABBREVIATIONS
ALT Alanine aminotransferase
AST Aspartate aminotransferase
CMPL Treatment compliance
Css Steady state concentration
DFO Deferoxamine
FT4 Free T4
IIV Inter-individual variability
IOV Inter-occasion variability
M&S Modelling and simulations
NPDE Normalised predictive distribution error
NTBI Non-transferrin bound iron
OFV Objective function value
PKPD Pharmacokinetic-pharmacodynamic
PRED Population prediction
RBC Red blood cells
TSH Thyroid-stimulating hormone
VPC Visual predictive check
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INTRODUCTION
Transfusional Iron Overload
Beta-thalassaemia major is a hereditary blood disorder and
patients affected by this disease require regular red blood cell
(RBC) transfusions to survive (1–7).Without the chronic trans-
fusion regimen, patients would die before the third decade of
life (2,4,5,7,8). Even though a significant improvement has
been achieved in the management of the chronic transfusion
regimen in the past decades, the therapy will eventually lead to
a series of complications. Iron overload is the most common
and relevant one and it is associated with several co-
morbidities such as cardiac dysfunction, liver fibrosis,
hypogonadism, hypothyroidism, hypoparathyroidism and di-
abetes mellitus (6,9,10). Cardiac disease caused by myocardial
siderosis is the most relevant complication, causing death
in 71% of the patients affected by transfusion-dependent
diseases (11).
For a complex process such as iron overload, understand-
ing of the dynamics of the disease and its progression is crucial
to adequately evaluate the impact of a therapeutic interven-
tion. This complexity is characterised also by the fact that the
biomarker ferritin does not provide a direct link between total
body or tissue iron accumulation at specific time points. The
absence of such a relationship is partly explained by the influ-
ence of other pathological mechanisms (e.g., inflammatory
disorders, and/or liver status) which can affect the iron inter-
change between organs and the circulatory system (2,12–14).
On the other hand, changes in ferritin levels are still helpful for
the management of the disease and maintaining serum ferritin
below a threshold of about 2500 μg/L is a widely accepted
therapeutic goal (2,3,5–7). Nonetheless, several clinical ques-
tions are not yet fully explored, e.g., howmuch time is required
in order to observe a true response, or in order to reach clin-
ically safe serum ferritin levels.
Iron Chelation Therapy with Deferoxamine
Given that the ability of our body to remove the excess of iron
is limited to a maximum of 1–2 mg/day (e.g., loss of intestinal
cells), treatment with iron chelators is vital to prevent its accu-
mulation and related complications (15–18). In this analysis
we are mainly interested in the iron chelating agent deferox-
amine. Deferoxamine was the first iron chelator approved for
human use and has been available for the treatment of iron
overload for more than 35 years (2,6,15–19). It is an
exadentate chelator that binds iron in a 1:1 ratio. The drug
is rapidly absorbed after intramuscular and subcutaneous ad-
ministration, but it cannot be absorbed orally. Several dosing
regimens and routes of administration have been proposed
and used in the past for deferoxamine in patients affected by
transfusion-dependent haemoglobinopathies but in the
majority of cases it is given as an 8 to 12 h nightly subcutane-
ous infusion (5 to 7 days a week) (2,19–21). The serum protein
binding is less than 10% and the drug undergoes the following
metabolic reactions: transamination and oxidation; beta-
oxidation; decarboxylation and N-hydroxylation. The aver-
age recommended daily dose lies between 20 and 60 mg/kg
and in patients with haemochromatosis the drug has an half-
life of 5.6 h (20–22).
Deferoxamine binds free iron by preventing the uptake of
NTBI (Non-Transferrin Bound Iron) into organs but it also
acts within the cell where it enters by endocytosis, stimulates
the degradation of ferritin via the lysosomes and subsequently
binds the realeased iron. The iron bound to deferoxamine is
then excreted in urine and feces (2,6,21,23).
Despite the availability of new oral iron chelators and several
limitations regarding the use of deferoxamine, such as compli-
ance issues due to the parenteral administration, inadequate
cardiac iron removal and auditory, ocular and neurological
toxicities (6,16,18,19,24), deferoxamine is still the most com-
mon used therapy for the treatment of iron overload.
The current investigation focuses on the use of a model-
based approach to gain insight into key factors that play a role
in iron overload, with the objective of quantifying the thera-
peutic effect of deferoxamine and characterising the role of
relevant covariates on the underlying disease progression. Fur-
thermore, we show how modelling and simulation (M&S) can
be applied to support decision making in clinical practice pro-
viding a framework to predict changes in the disease status and
the evaluate the impact of predefined therapeutic regimens.
METHODS
Data
The data analysis was performed using retrospective clinical
data from three different Italian centres: A.O. Universitaria
Consorziale Policlinico di Bari U.O. Pediatria Federico
Vecchio; A.O. Universitaria Policlinico di Sassari Clinica
Pediatrica, ASL 1 D.H. Per Talassemia; A.O. di Padova
Clinica di Oncoematologia Pediatrica. The study has been
conducted in full conformance with the principles of the Dec-
laration of Helsinki and with the local laws and regulations
concerning clinical trials. The protocol and the informed con-
sent documents have been formally approved by the relevant
research ethics committee of each clinical site.
Clinical data were collected retrospectively for a maximum of
10 years from 27 patients affected by transfusion-dependent dis-
eases, receiving deferoxamine asmonotherapy for iron chelation.
Patients were followed according to standard clinical practice,
which includes case specific dose adjustments. Modifications to
the dosing regimen were recorded and transcribed into the anal-
ysis dataset; the most prevalent dose was 40 mg/kg. Baseline
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characteristics of the patient population are provided in Table I.
Serum ferritin was the main endpoint of interest and was mea-
sured every 2 to 3 months; patients contributed with 40.2 obser-
vations on average (sd: 17), with a minimum of 4 samples per
year.
PK Model of Deferoxamine
A two compartment pharmacokinetic model with zero-order
absorption (8 h subcutaneous infusion) and first-order elimina-
tion processes was used to describe the time course of deferox-
amine in plasma and subsequently derive the average steady
state concentration (CssAV) for the population of interest. De-
feroxamine plasma levels were based on the dosing regimen
information collected from the patients' medical history at the
clinical centres. The model was built using literature data (25)
by fitting a mean pharmacokinetic profile in adult patients
affected by transfusion-dependent haemoglobinopathies re-
ceiving a 40 mg/kg dose of deferoxamine as an 8 h subcuta-
neous infusion. The final PK parameters obtained as input for
the data analysis included apparent clearance (19.3 L/h),
intercompartmental clearance (17.6 L/h), apparent volume
of distribution (77.4 L) and apparent peripheral volume of
distribution (238.0 L). Subsequently fixed allometric scaling
(exponent of 0.75 on apparent clearances and 1.00 on the
apparent volumes of distribution) was used to extrapolate
CssAV in adolescents and children. Population prediction
(PRED) were used to generate CssAV values in the population
of interest. The fitting of the model is shown in Fig. 1.
Disease Model of Iron Overload
A disease model of iron overload in patients affected by
transfusion-dependent diseases was used to account for the
effect of blood transfusions on serum ferritin levels. It consisted
of an indirect response model where the basal turnover of
ferritin is depicted by a zero-order production rate (Kin) and
a first-order degradation rate (Kout) and the parameter de-
scribing the disease component is represented by an additive
production rate (CRT) triggered by the transfusion regimen,
which was found to be non-linearly correlated to the disease
status (actual ferritin levels).
dFERRITIN
dt
¼ Kin þ CRT−Kout  FERRITIN ð1Þ
CRT ¼ SCL  e−SHPFERRITIN ð2Þ
where SCL is a scaling factor and SHP is the shape factor of
the correlation between the disease status and the production
rate (CRT). The population parameters of the disease model
were kept fixed when performing the retrospective PKPD
analysis of the clinical data.
PKPD Modelling of Deferoxamine
The software R (v.2.14.0) (26) was used for statistical summaries
as well as data manipulation and preparation for modelling pur-
poses. Nonlinear mixed effects modelling was performed in
NONMEM version 7.2 (Icon Development Solutions, USA).
Model building criteria included: (i) successful minimisation,
(ii) standard error of estimates, (iii) number of significant digits,
(iv) termination of the covariance step, (v) correlation between
model parameters and (vi) acceptable gradients at the last itera-
tion. Comparison of nested hierarchical models was based on the
likelihood ratio test (LRT). Goodness of fit was assessed by graph-
ical methods, including population and individual predicted vs.
observed concentrations, conditional weighted residuals vs.
Table I Baseline Characteristics of the Patient Population (n=27) Included
in the Analysis
Units Median Range
Age Years 14.6 6.8–19.9
Weight kg 46 17.5–71
Height cm 154 111–173
TSH mIU/L 2.34 0.58–83.2
FT4 ng/dL 1.05 0.73–1.43
AST U/L 33 7–159
ALT U/L 56 9–372
Glucose mg/dL 91 52–444
Creatinine mg/dL 0.6 0.2–1.12
Ejection fraction % 64 35–77
Ferritin μg/L 2260 393–8500
Fig. 1 Predicted and observed pharmacokinetic profile of deferoxamine.
The circles represent the mean deferoxamine concentrations reported in
literature (25). The solid line represents the population model prediction.
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observed concentrations and time, correlation matrix for fixed vs.
random effects, correlation matrix between parameters and co-
variates and normalised predictive distribution error (NPDE) (27).
Fixed and random effects were introduced into the model
in a stepwise manner. Inter-individual variability and inter
occasion variability (IOV) in the model parameters was as-
sumed to be log-normally distributed. A parameter value of
an individual i (post hoc value) is therefore given by the fol-
lowing equation:
θi ¼ θTV*e ηiþIOVið Þ
in which θTV is the typical value of the parameter in the
population and ηi and IOVi are assumed to be random vari-
ables with zero mean and variance ω2. Residual variability,
which comprises measurement and model error, was de-
scribed by a proportional error model. This means that for
the jth observed concentration of the ith individual, the follow-
ing relation applies:
Yi j ¼ Fi j þ εi j*W
where Fij is the predicted concentration, εij is a random vari-
able with mean zero and variance σ2, andW is a proportional
weighing factor for ε.
Different concentration-effect relationships (e.g., Emax
model, linear model, etc.) were tested on the disease model
presented in Eq. 1 to characterise the effect of deferoxamine
on serum ferritin levels. Deferoxamine average steady-state
concentrations (CssAV) generated with the PK model de-
scribed above were used as a measure of drug exposure.
The effect of deferoxamine (DFO) was introduced in a pro-
portional way on the degradation rate (Kout) of ferritin as
shown in Eq. 3 which is derived from Eq. 1.
dFERRITIN
dt
¼ Kin þ CRT−Kout  FERRITIN
 1þ DFOð Þ ð3Þ
DFO ¼ SLP  SCssAV ð4Þ
whereDFO is the effect of deferoxamine on the degradation rate
(Kout) of the disease model, SLP is the slope parameter of the
concentration-effect relationship, and SCssAV are the steady state
concentrations simulated with the deferoxamine PK model.
In addition, two disease model parameters, namely, the
scaling (SCL) and the shape (SHP) factors presented in Eq. 2
were found to be non-linearly correlated with the actual dis-
ease status according to the following relationships:
SCLi ¼ SCLre f  FERRITINFERRITIN med
 θx
ð5Þ
SHPi ¼ SHPre f  FERRITINFERRITIN med
 θx
ð6Þ
where SCLref and SHPref are the reference parameters in the
population of interest, SCLi and SHPi are the individual param-
eters, FERRITINmed is the median ferritin value in the popula-
tion of interest and θx is the estimated exponent of the
relationship.
The validation of the final model was based on graphical and
statistical methods, including visual predictive checks (28). Boot-
strap (1000 samples) was used to identify bias, stability and accu-
racy of the parameter estimates (standard errors and confidence
intervals). The bootstrap procedures were performed in PsN
v3.5.3 (University of Uppsala, Sweden) (29), which automatically
generates a series of new data sets by sampling individuals with
replacement from the original data pool, fitting the model to
each new data set.
Evaluation of the Role of Compliance
At an early stage of the model building phase model
misspecification was observed, as the model could not appropri-
ately describe the data (See supplemental material, Figure 1S)
based on the assumption that the population under investigation
as one single population. In fact, two different ferritin profiles
were identified and patients were initially considered as re-
sponders and non-responders. The responders showed very sta-
ble profiles around 2500 μg/L serum ferritin, whereas the non-
responders showed very steep increases in ferritin levels and ap-
peared not to be able to return to a less severe state of the disease.
A mixture model improved the quality of the fitting but would
still not allow an adequate characterisation of the individual pro-
files. Demographic factors were compared among the two sub-
populations and no significant differences were identified that
could justify the difference in response to treatment.
We have therefore decided to investigate the possible mecha-
nisms responsible for the different response profiles using the
information available in the literature. Treatment compliance
was found to be the major cause of these differences. In the
papers byGabutti et al. (30) andGalanello et al. (31) serum ferritin
profiles are quite stable over the observational period (See Fig. 1
and supplemental material Figure 2S) as in our responder group
and compliance is in both cases higher than 95%. In other in-
vestigations (20,30,32) Kaplan-Meier analyses show the relation-
ship between survival and treatment compliance, providing
evidence of the fact that poor adherence has a major impact
on response. In particular the work by Olivieri et al. (32) shows
how survival can directly be linked to the observed ferritin levels.
The absence of quantitative data on treatment compliance in
our retrospective study did not allow us to directly use this vari-
able to account for such differences and was a clear obstacle for
the analysis. To overcome this limitation we used the work
carried out by Olivieri et al. (32) as a reference and derived a
new variable (CMPL) based on the percentage of observations
for each patient above the threshold of 2500 μg/L ferritin.
CMPL had a median value of 21% (range of 0–100) and mean
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of 32% (95% CI: 0.9–98%) in the population under investiga-
tion. The new variable (CMPL)was introduced into themodel as
follows:
DFO ¼ SLP  TCAVss ð7Þ
TCAVss ¼ SCAVss  1−CMPLð Þ ð8Þ
where DFO is the effect of deferoxamine, SLP is the slope pa-
rameter of the concentration-effect relationship, and TCssAV is
the “true” steady state concentration after accounting for the
impact of treatment compliance (CMPL). TCssAV values are
derived from the simulated steady state concentrations (SCssAV)
corrected for treatment compliance as shown in Eq. 7.
The incorporation of treatment compliance into the model
provided a significant improvement in the fitting of the data (as
shown in Fig. 2 and supplemental material Figure 2S) and
allowed a more accurate description of the therapeutic
intervention.
Simulation Scenarios (Decision-Making in Clinical
Practice)
Simulations were performed to investigate the impact of different
exposure levels and various compliance scenarios on the clinical
response, as assessed by serum ferritin levels. Time to reach
2500 μg/L serum ferritin (threshold between moderate and se-
vere iron overload (2,6,20,32,33)) was chosen as a comparison
measure between different scenarios. The differential equation
solver ode15s from the softwareMATLAB (versionR2010b) (34)
was used for the simulations, whereas the software R (v.2.14.0)
(26) was used for graphical summaries. The ode15s, which is a
multistep solver and uses numerical differentiation formulas, is
particularly suitable for stiff systems (35,36).
Three dosing regimens (30, 45 and 60 mg/kg/day for 5 days
a week) were used to generate CssAV in a patient population with
body weight ranging from 15 to 75 kg. A visual representation of
the CssAV by body weight for the three dosing regimens can be
found in Fig. 3. This enabled the assessment of the impact of
different exposures on the endpoint of interest (time to reach the
threshold). Each exposure level was then tested on patients
starting at different baselines ranging from 3000 to 12,
000 μg/L serum ferritin. In this set of simulations the exposure
was assumed to be constant over time.
In addition, simulation scenarios were evaluated to character-
ise the impact of various compliance scenarios on changes in
ferritin levels. Our main interest in this case was to show how a
drug-disease model can be used prospectively in clinical practice
to predict individual patient response. Given the large number of
scenarios that were evaluated here, the discussion and presenta-
tion of the results will be limited to the case in which a virtual
patient of 45 kg receives 45mg/kg/day deferoxamine 5 days per
week. The different scenarios investigated are also presented in
Table II, where compliance is stratified into four groups: 1 year,
6 months, 2 months and 1 month. Compliance patterns in each
Fig. 2 Individual plots of 9
randomly selected patients:
observed data are shown as blue
circles; the black and red solid lines
represent, respectively, the
population (Pred) and individual
predictions (IPred).
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group were further clustered into two categories, namely 1) poor
quality of execution, i.e., missed single doses at random, and 2)
drug holidays, i.e., doses that are missed consecutively during a
given period of time. For example, in the poor quality of execu-
tion scenario, missing 40% of the doses at random means that
100 single doses were missed randomly over a period of 1 year;
whereas in the drug holidays scenario, missing 40% of the doses
means missing 100 consecutive doses over a period of 1 year (i.e.,
the first 100 doses are missed and the remaining 150 are taken).
The iterations were stopped if more than 5 years were needed to
reach the threshold of 2500 μg/L serum ferritin. Five years were
considered as a clinically relevant time limit for the purposes of
the analysis. Patients reaching the predefined ferritin threshold in
more than 5 years do not influence the results of the analysis or
the comparison of the treatment response for the different dosing
regimens and compliance patterns.
Fig. 3 Average steady state
concentration by body weight for 7
typical individuals receiving three
different deferoxamine doses: 30
(- - -), 45 (....) and 60 (-.-.-) mg/kg/
day.
Table II Simulation Scenarios for the Evaluation of Different Compliance Levels. Full Adherence is Equivalent to 250 Doses Per Year
% of missed doses Number of missed doses during the stratification period
Missed single doses at random Missed consecutive doses (i.e., drug holidays)
Stratification
1 year 1 year 6 months 2 months 1 month
Scenario 1 10% 25 25 / 5 /
Scenario 2 20% 50 50 25 10 5
Scenario 3 30% 75 75 / 15 /
Scenario 4 40% 100 100 50 20 10
Scenario 5 50% 125 125 / 25 /
Scenario 6 60% 150 150 75 30 15
Scenario 7 70% 175 175 / 35 /
Scenario 8 80% 200 200 100 40 20
Scenario 9 90% 225 225 / 45 /
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RESULTS
Disease Model
As described in the methods a disease model was previously
developed for iron overload [unpublished results] and its perfor-
mance in describing the impact of blood transfusions on serum
ferritin was confirmed in this analysis. The effect of blood trans-
fusions was introduced as a conversion rate on the production
rate of ferritin, which was found to be inversely correlated with
the disease status, as shown in Eqs. 1 and 2. In addition, two
disease model parameters, namely, the scaling (SCL) and the
shape (SHP) factors presented in Eq. 2 were found to be non-
linearly correlated with the actual disease status. Their inclusion
in the model provided a significant decrease in the objective
function value (OFV) and allowed a better description of the
data. Further improvement was obtained after the inclusion of
inter-occasion variability (IOV=57.4%) on the conversion rate,
which resulted in a significant drop in the OFV (Δ 443) allowing
a better description of the individual profiles.
Drug Model
The effect of deferoxamine (DFO) was introduced in a propor-
tional way on the degradation rate (Kout) of ferritin. A linear
model was preferred to a non-linear model (i.e., Emax) given the
fact that it accurately described the changes in ferritin observed
clinically. The limited range of doses and number of patients did
not provide sufficient information to support the characterisation
of a non-linearmodel. Furthermore, the implementation of treat-
ment compliance as a factor on the exposure of deferoxamine
improved considerably the quality of the fitting and the model
performance. The inclusion of inter-individual variability (IIV)
on the slope parameter also reduced significantly the OFV and
improved goodness of fit and visual predictive check (VPC) di-
agnostics. An overview of the final model parameters and boot-
strap results is presented in Table III.
Internal model validation diagnostics were satisfactory. In-
dividual predicted profiles and goodness-of-fit plots, as shown
in Fig. 2 and supplemental material figures 2S along with
VPC results (Fig. 4) reveal that the model provides an ade-
quate and unbiased description of the data. In addition,
NPDE summaries (figure 3S) show that the discrepancy be-
tween predicted and observed values can be assumed to be
normally distributed.
Simulation Scenarios (Decision-Making in Clinical
Practice)
The impact of different exposure levels and varying compli-
ance levels on the clinical response, as assessed by serum fer-
ritin levels was evaluated through model simulations. A sum-
mary of the results stratified by body weight and ferritin levels
at the start of treatment is presented in Fig. 5 for the following
dosing regimens: 30, 45 and 60 mg/kg/day for 5 days a week.
Results clearly show that an appropriate clinical response can-
not be achieved without adequate exposure to the chelating
agent. The model also provides the opportunity to evaluate a
priori the most suitable dosing regimen to achieve a desired
therapeutic goal.
Finally, we have investigated the impact of different com-
pliance patterns on the time to reach the threshold of
2500 μg/L serum ferritin. Whereas simulations refer to one
virtual patient of 45 kg receiving 45mg/kg/day deferoxamine
5 days per week, several conclusions can be derived from these
results: 1) a better and faster response is achieved if single doses
are missed at random (reflecting poor quality of execution)
(Fig. 6—scenario 1) as compared to doses missed consecutive-
ly (drug holidays) (Fig. 6—scenario 2) over a period of 1 year;
2) if doses aremissed consecutively over a given period of time,
the shorter the period the better the clinical response (as
shown in Fig. 6—scenarios 2 to 5); 3) in all the scenarios, if
more than 60% of the doses are missed (treatment compliance
is lower than 40%) the therapeutic intervention is not effective;
and finally 4) a reduction in treatment compliance, especially
when moving from 30 to 60% of missed doses clearly leads to
a significantly slower response. These findings indicate that
even if the desired therapeutic outcome can be achieved the
time to reach the proposed threshold might not be sustainable
for the patient.
DISCUSSION
A model-based approach is proposed here as a tool for the
evaluation of the impact of disease-, patient- and drug specific
factors on iron chelation therapy in patients affected by
transfusion-dependent haemoglobinopathies. The complexity
Table III Parameter Estimates of the PKPD Model of Deferoxamine
Parameter Estimate Bootstrap (mean) CV (%)
Kin (μg/h) 0.0002 (FIX) / /
Kout (h−1) 0.0000045 (FIX) / /
SHP (h−1) 0.00026 (FIX) / /
SCL (μg/h) 0.383 (FIX) / /
Slope (μg/conc) 4.81 5.16 15.7
Error proportional −0.173 −0.17 6.5
DIS exp on SHP 1.29 1.08 57.4
DIS exp on SCL 0.845 0.67 51.9
IIV on Slope 0.082 0.105 80.9
IOV on CRT 0.252 0.29 43.1
CRT production rate due to transfusion regimen, SHP shape factor, SCL scaling
factor, DIS disease status, IIV interindividual variability, IOV inter-occasion vari-
ability, CV coefficient of variation, Bootstrap 1000 samples
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of iron homeostasis and more specifically the ferritin response
to chelation therapy requires an integrated approach that al-
lows exploring the dynamics of iron overload and its progres-
sion. A drug-disease model was successfully developed and
validated as shown in Table III and supplemental figures 2S
and 3S. The analysis reveals a strong effect of the disease status
on the overall iron/ferritin conversion rate, and highlights the
role of treatment (drug exposure and compliance patterns) on
the overall response and disease progression.
Simulation scenarios were used to investigate the impact of
different exposure levels as well as the effect of varying pat-
terns of compliance on serum ferritin levels. Results show that
inadequate iron chelation therapy with sub-therapeutic expo-
sure (Fig. 5) as well as poor adherence to the assigned dosing
regimen (Fig. 6) significantly increase the time required to
achieve a desired clinical response, and in some cases (e.g., with
treatment compliance lower than 40%) the therapeutic goal
cannot be achieved at all. Even though these results might
seem rather obvious, we are aware that clinically relevant
changes in serum ferritin levels take place over a somewhat
long period of time, and often crucial decisions have to be
made before the clinical evidence is available. Our approach
offers an opportunity to explore different scenarios before
medical decisions have to be made. For example, the use of
simulation scenarios may provide insight into whether lower-
ing the dose (i.e., a trade-off for a possible reduction in acute
side effects) and an increased time to achieve the therapeutic
goal would be sustainable for the patient. In the same way,
given the importance of treatment compliance for a drug
such as deferoxamine, the evaluation of simulation sce-
narios allows a more quantitative evaluation of the im-
pact of different compliance patterns. This information
can be used to support the decision making and to opti-
mise the therapeutic intervention.
Limitations
Some limitations must be considered in the context of
this analysis. First of all, we developed a PK model based
on literature data, which allowed us to use fixed allome-
tric scaling, including mean population data and individ-
ual information. A more structured analysis of the PK of
deferoxamine would reduce the uncertainty around the
simulated exposure and explain part of the variability in
PK that propagates into the pharmacodynamic parame-
ter estimates. On the other hand, the proposed approach
allowed us to characterise differences in the pharmacoki-
netics that could not have been evaluated based only on
information about the dosing regimen; e.g., changes in
size are accounted for by allometric scaling.
A second aspect is the role of treatment compliance.
The lack of quantitative data on adherence in the pop-
ulation under investigation was a clear impediment for
the analysis. To overcome this issue we used the ob-
served data to generate a variable that captures differ-
ences in compliance. This decision was supported by the
Fig. 4 Visual predictive check:
observed data are depicted by grey
circles; the red and blue solid line
represent, respectively, the median
and the 5th and 95th percentiles of
the observed data. The red and blue
shaded area represent, respectively,
the 95th CI of the median and the
95th CI of the 5th and 95th
percentiles of the simulated data.
Optimisation of DFX chelation therapy 505
information available in the literature; we found clear
evidence that high compliance leads to stable ferritin
leve l s over t ime and that poor adherence to
deferoxamine therapy is strongly correlated with poor
clinical outcome, as nicely depicted in the work by
Gabutti et al. (30) (Kaplan-Meier analysis presented in
Fig. 2). This was confirmed by a few other publications
(20,31,32,37) and gave us the confidence that the ap-
proach taken here would be robust enough for the
purposes of this analysis. In addition, we should empha-
sise that whilst not all levels of compliance have been
tested, linear interpolation between scenarios does not
affect the overall conclusions that can be drawn from
the simulation results. For instance, the impact of 50%
compliance can be inferred from data showing response
for patients with 40 and 60% missed doses (see Fig. 6).
Of course, additional simulations would need to be per-
formed to obtain accurate figures for this scenario.
Fig. 5 Time to reach a serum
ferritin threshold of 2500 ug/L for
varying exposure levels in patients
with different body weights (15 to
75 kg). The panels show three
scenarios where 30, 45 and
60 mg/kg dosing regimen were
evaluated. Each line represents a
different starting baseline ferritin
level (darker to lighter shows an
increase in the starting baseline
levels). Square, circle, triangle with
point up, plus, cross, diamond,
triangle with point down, square cross,
star and diamond plus represent
starting baseline ferritin values,
respectively of 3000, 4000, 5000,
6000, 7000, 8000, 9000, 10,000,
11,000 and 12,000 ug/L. The
dashed horizontal lines represent
indicative thresholds at 6 months, 1,
2, 3, 4 and 5 years.
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CONCLUSION
In conclusion, modelling of ferritin response enables charac-
terisation of the dynamics of iron overload in patients receiv-
ing chronic blood transfusions. Of note is the possibility to
predict the time to achieve clinically safe levels of ferritin in
individual patients. The approach can be used to support
decision making in clinical practice, including personalisation
of the dose for existing and novel chelating agents. Bearing in
mind the limitations discussed above and the relative level of
uncertainty, this model can be expanded to other transfusion-
dependent haemoglobinopathies.
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